La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Synmosa Biopharma Crescita futura

Future criteri di controllo 1/6

Si prevede che Synmosa Biopharma aumenterà i ricavi a una percentuale annua pari a 12.8%.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.1%
Tasso di crescita dei ricavi	12.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	03 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

Previsioni di crescita degli utili e dei ricavi

TPEX:4114 - Stime future degli analisti e dati finanziari passati (TWD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	6,250	N/A	897	1,047	1
12/31/2024	5,464	N/A	786	936	1
6/30/2024	5,186	689	235	531	N/A
3/31/2024	5,164	650	241	522	N/A
12/31/2023	5,140	595	251	512	N/A
9/30/2023	5,059	585	204	470	N/A
6/30/2023	4,931	562	358	614	N/A
3/31/2023	4,677	800	337	570	N/A
12/31/2022	4,386	799	446	630	N/A
9/30/2022	4,048	735	426	585	N/A
6/30/2022	3,721	693	466	594	N/A
3/31/2022	3,441	368	394	536	N/A
12/31/2021	3,235	304	313	455	N/A
9/30/2021	3,141	288	403	520	N/A
6/30/2021	3,105	293	218	350	N/A
3/31/2021	3,012	634	244	379	N/A
12/31/2020	3,038	638	77	254	N/A
9/30/2020	2,931	582	-52	140	N/A
6/30/2020	2,861	519	-136	67	N/A
3/31/2020	2,849	95	-316	-104	N/A
12/31/2019	2,680	47	-247	-45	N/A
9/30/2019	2,579	40	-321	-54	N/A
6/30/2019	2,486	61	-292	-11	N/A
3/31/2019	2,384	73	-249	128	N/A
12/31/2018	2,363	431	-350	16	N/A
9/30/2018	2,249	432	-276	-106	N/A
6/30/2018	2,119	409	-141	57	N/A
3/31/2018	2,017	379	N/A	9	N/A
12/31/2017	1,861	5	N/A	-5	N/A
9/30/2017	1,795	-34	N/A	76	N/A
6/30/2017	1,772	-38	N/A	20	N/A
3/31/2017	1,821	-6	N/A	144	N/A
12/31/2016	1,865	165	N/A	236	N/A
9/30/2016	1,894	173	N/A	279	N/A
6/30/2016	1,926	180	N/A	186	N/A
3/31/2016	1,856	180	N/A	82	N/A
12/31/2015	1,776	32	N/A	24	N/A
9/30/2015	1,706	58	N/A	-30	N/A
6/30/2015	1,644	75	N/A	-43	N/A
3/31/2015	1,562	97	N/A	-118	N/A
12/31/2014	1,476	110	N/A	-11	N/A
9/30/2014	1,423	122	N/A	21	N/A
6/30/2014	1,329	107	N/A	28	N/A
3/31/2014	1,275	91	N/A	76	N/A
12/31/2013	1,249	63	N/A	30	N/A
9/30/2013	1,207	50	N/A	78	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 4114 è superiore al tasso di risparmio ( 1% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 4114 cresceranno più velocemente del mercato TW

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 4114 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 4114 ( 12.8% all'anno) crescerà più rapidamente del mercato TW ( 11.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4114 ( 12.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 4114 è previsto essere elevato tra 3 anni

Synmosa Biopharma Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Price target raised to NT$28.00

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.53 (vs NT$0.42 in 2Q 2023)

Synmosa Biopharma Corporation to Report Q2, 2024 Results on Aug 13, 2024

Dividend of NT$0.60 announced

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 13, 2024

First quarter 2024 earnings released: EPS: NT$0.48 (vs NT$0.35 in 1Q 2023)

Synmosa Biopharma Corporation to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita